Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration; electrolytes correct imbalances; low magnesium and calcium adjust levels in renal failure.
Delflex with Dextrose 3.5% is a peritoneal dialysis solution that uses a high concentration of dextrose to create an osmotic gradient, drawing water and solutes from the blood across the peritoneal membrane into the dialysate, thereby removing excess fluid and waste products from the body. Dextrose is metabolized locally and systemically.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or 8-10 liters over 10-12 hours for overnight cycler, with dextrose concentration selected based on ultrafiltration needs.
Intraperitoneal administration: 2000 mL per exchange, typically 4 exchanges per day, with dwell times of 4-6 hours (CAPD) or cycler-adjusted for APD.
None Documented
None Documented
Not applicable as a terminal half-life for the solution itself; glucose absorption half-life from peritoneal cavity is approximately 2-4 hours, reflecting peritoneal clearance. There is no systemic accumulation of the solution's components beyond expected glucose metabolism.
3-5 hours (prolonged in renal impairment; anuria up to 24-36 hours)
Primarily eliminated via peritoneal drainage during continuous ambulatory peritoneal dialysis (CAPD). Approximately 60-80% of glucose is absorbed across the peritoneum and metabolized systemically; non-metabolized glucose and other solutes are removed in dialysate effluent. Renal excretion is negligible (<5%) in patients with end-stage renal disease on CAPD.
Renal: >90% unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution